July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

Zejula improves 1L ovarian cancer PFS
Zejula niraparib met the primary endpoint in the Phase III PRIMA trial to treat first-line ovarian cancer following platinum chemotherapy, significantly improving progression-free survival regardless of patients' biomarker status vs. placebo. The PARP

Read the full 389 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE